Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Tural, D, Serdengecti, S, Demirelli, F, Öztürk, T, İlvan, S, Turna, H, Özgüroglu, M, Büyükünal, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Retraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056067/
https://www.ncbi.nlm.nih.gov/pubmed/24919019
http://dx.doi.org/10.1038/bjc.2014.314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056067/
https://www.ncbi.nlm.nih.gov/pubmed/24919019
http://dx.doi.org/10.1038/bjc.2014.314

Ejemplares similares